European Companies Search Engine
EU funding (€3,959,507): Intelligent design of adenovirus vectors (iAds) Hor7 Mar 2023 EU Research and Innovation programme "Horizon"
Text
Intelligent design of adenovirus vectors (iAds)
Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene transfer is inherently and intransigently linked to vector efficacy. Partially due to the lack of suitable delivery systems for particular applications, the success of too many gene therapies is limited. Over the last two decades, immense progress has been made in the development of viral vectors. Importantly, this progress has also identified vector characteristics and biological factors that decrease efficacy. While limited efficacy is relevant for all vector platforms, it is more pressing in the case of adenoviruses because they have so much potential. In some cases, host responses and imperfect targeting have stunted adenovirus vector development for therapies that require long-term transgene expression. Our multi-faceted consortium proposes an innovative approach to overcome these limitations and to construct a pathway for developing improved vectors for clinical gene transfer. By synergising French, Dutch, British, Spanish and Swedish expertise in structural biology, receptor engagement, neurobiology, cardiobiology, and bioprocessing, we will create in silico designed intelligent adenovirus vectors (iAds). Our disruptive concept abandons the classical approach of developing vectors from naturally occurring adenoviruses. Instead, a proprietorial adenovirus type will be serially stripped of unwanted elements to create a bank of iAds, which will then be engineered for heart- and brain-specific targeting. Our consortium blends academic ingenuity and SME/pharma manufacturing that will allow seamless clinical translation. With the support of the EIC Programme, our ground-breaking approach should revolutionise gene transfer and generate solutions in areas of unmet medical need via a platform that exploits the full potential of viral vectors.
Funded Companies:
| Company name | Funding amount |
| The University of Edinburgh | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €645,119 |
| Batavia Biosciences B.V. | €405,101 |
| Centre National de la Recherche Scientifique CNRS | €1,483,978 |
| Institut National de la Sante et de la Recherche Medicale | €0.00 |
| Janssen Vaccines & Prevention B.V. | €531,169 |
| Umea Universitet | €429,408 |
| Universite de Montpellier | €0.00 |
| Vilniaus Universitetas | €464,733 |
Source: https://cordis.europa.eu/project/id/101098647
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: The University of Edinburgh, Edinburgh.